Role of statins in the treatment of multiple sclerosis

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Statins as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase are widely prescribed for hypercholesterolemia treatment. In the last years, statins have also been shown to exert immunomodulatory and anti-inflammatory effects which appear to be related to inhibition of isoprenylation of small GTP-binding proteins and, at least in part, independent of their cholesterol-lowering effects. These "pleiotropic" effects make statins an attractive treatment option for immune-mediated disorders such as multiple sclerosis. Studies in vitro and in experimental autoimmune encephalomyelitis animal model seem to support not only the efficacy of statins as immunomodulatory agents but also their potential neuroprotective properties, although the exact mechanism with which statins exert these effects has not yet been fully understood. The immunomodulatory, anti-inflammatory and neuroprotective properties of statins provided the incentive for several clinical trials in multiple sclerosis, in which they were tested not only as mono-therapy but also in combination with interferon-β. However, the attempt to translate the results of animal model studies in humans produced conflicting results. Further large, prospective, randomized, double-blind, placebo-controlled trials, designed to evaluate the long-term effects of statins alone or in add-on to other disease-modifying therapies, are needed to support their routine clinical use in multiple sclerosis.

Original languageEnglish
Pages (from-to)133-143
Number of pages11
JournalPharmacological Research
Volume87
DOIs
Publication statusPublished - 2014

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Multiple Sclerosis
Therapeutics
Anti-Inflammatory Agents
Animal Models
Prenylation
Autoimmune Experimental Encephalomyelitis
Immune System Diseases
Hypercholesterolemia
GTP-Binding Proteins
Interferons
Motivation
Oxidoreductases
Cholesterol
Placebos
Clinical Trials

Keywords

  • Combination therapy
  • Immunomodulatory effect
  • Multiple sclerosis
  • Neuroprotection
  • Randomized clinical trial
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Medicine(all)

Cite this

Role of statins in the treatment of multiple sclerosis. / Ciurleo, Rosella; Bramanti, Placido; Marino, Silvia.

In: Pharmacological Research, Vol. 87, 2014, p. 133-143.

Research output: Contribution to journalArticle

@article{a9e96716ef984487990ab7509fdf18bb,
title = "Role of statins in the treatment of multiple sclerosis",
abstract = "Statins as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase are widely prescribed for hypercholesterolemia treatment. In the last years, statins have also been shown to exert immunomodulatory and anti-inflammatory effects which appear to be related to inhibition of isoprenylation of small GTP-binding proteins and, at least in part, independent of their cholesterol-lowering effects. These {"}pleiotropic{"} effects make statins an attractive treatment option for immune-mediated disorders such as multiple sclerosis. Studies in vitro and in experimental autoimmune encephalomyelitis animal model seem to support not only the efficacy of statins as immunomodulatory agents but also their potential neuroprotective properties, although the exact mechanism with which statins exert these effects has not yet been fully understood. The immunomodulatory, anti-inflammatory and neuroprotective properties of statins provided the incentive for several clinical trials in multiple sclerosis, in which they were tested not only as mono-therapy but also in combination with interferon-β. However, the attempt to translate the results of animal model studies in humans produced conflicting results. Further large, prospective, randomized, double-blind, placebo-controlled trials, designed to evaluate the long-term effects of statins alone or in add-on to other disease-modifying therapies, are needed to support their routine clinical use in multiple sclerosis.",
keywords = "Combination therapy, Immunomodulatory effect, Multiple sclerosis, Neuroprotection, Randomized clinical trial, Statins",
author = "Rosella Ciurleo and Placido Bramanti and Silvia Marino",
year = "2014",
doi = "10.1016/j.phrs.2014.03.004",
language = "English",
volume = "87",
pages = "133--143",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press",

}

TY - JOUR

T1 - Role of statins in the treatment of multiple sclerosis

AU - Ciurleo, Rosella

AU - Bramanti, Placido

AU - Marino, Silvia

PY - 2014

Y1 - 2014

N2 - Statins as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase are widely prescribed for hypercholesterolemia treatment. In the last years, statins have also been shown to exert immunomodulatory and anti-inflammatory effects which appear to be related to inhibition of isoprenylation of small GTP-binding proteins and, at least in part, independent of their cholesterol-lowering effects. These "pleiotropic" effects make statins an attractive treatment option for immune-mediated disorders such as multiple sclerosis. Studies in vitro and in experimental autoimmune encephalomyelitis animal model seem to support not only the efficacy of statins as immunomodulatory agents but also their potential neuroprotective properties, although the exact mechanism with which statins exert these effects has not yet been fully understood. The immunomodulatory, anti-inflammatory and neuroprotective properties of statins provided the incentive for several clinical trials in multiple sclerosis, in which they were tested not only as mono-therapy but also in combination with interferon-β. However, the attempt to translate the results of animal model studies in humans produced conflicting results. Further large, prospective, randomized, double-blind, placebo-controlled trials, designed to evaluate the long-term effects of statins alone or in add-on to other disease-modifying therapies, are needed to support their routine clinical use in multiple sclerosis.

AB - Statins as inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase are widely prescribed for hypercholesterolemia treatment. In the last years, statins have also been shown to exert immunomodulatory and anti-inflammatory effects which appear to be related to inhibition of isoprenylation of small GTP-binding proteins and, at least in part, independent of their cholesterol-lowering effects. These "pleiotropic" effects make statins an attractive treatment option for immune-mediated disorders such as multiple sclerosis. Studies in vitro and in experimental autoimmune encephalomyelitis animal model seem to support not only the efficacy of statins as immunomodulatory agents but also their potential neuroprotective properties, although the exact mechanism with which statins exert these effects has not yet been fully understood. The immunomodulatory, anti-inflammatory and neuroprotective properties of statins provided the incentive for several clinical trials in multiple sclerosis, in which they were tested not only as mono-therapy but also in combination with interferon-β. However, the attempt to translate the results of animal model studies in humans produced conflicting results. Further large, prospective, randomized, double-blind, placebo-controlled trials, designed to evaluate the long-term effects of statins alone or in add-on to other disease-modifying therapies, are needed to support their routine clinical use in multiple sclerosis.

KW - Combination therapy

KW - Immunomodulatory effect

KW - Multiple sclerosis

KW - Neuroprotection

KW - Randomized clinical trial

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84907598207&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907598207&partnerID=8YFLogxK

U2 - 10.1016/j.phrs.2014.03.004

DO - 10.1016/j.phrs.2014.03.004

M3 - Article

C2 - 24657241

AN - SCOPUS:84907598207

VL - 87

SP - 133

EP - 143

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

ER -